Improving CAR T-cell therapy for patients with relapsed lymphoma
LTBR CARs as next-generation therapies for R/R lymphoma
['FUNDING_R01'] · NEW YORK GENOME CENTER · NIH-11045028
This study is looking at how to make CAR T-cell therapy work better for people with tough-to-treat diffuse large B-cell lymphoma by exploring a special receptor in T-cells that might help them fight cancer more effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK GENOME CENTER (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11045028 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of CAR T-cell therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The team is investigating the role of the lymphotoxin beta receptor (LTBR) in T-cells, which may improve their ability to fight cancer by reducing exhaustion and boosting anti-tumor responses. By analyzing patient samples and conducting functional assays, the researchers aim to develop a more effective CAR T-cell treatment that could lead to better outcomes for patients. If successful, this approach could provide a new avenue for patients who have not responded well to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma who have not responded to first-line treatments.
Not a fit: Patients with early-stage lymphoma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T-cell therapies, improving survival rates and quality of life for patients with relapsed lymphoma.
How similar studies have performed: Previous research has shown promise in enhancing CAR T-cell therapies, but the specific approach using LTBR is novel and has not been extensively tested.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK GENOME CENTER — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SANJANA, NEVILLE — NEW YORK GENOME CENTER
- Study coordinator: SANJANA, NEVILLE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.